The work described herein defined a crucial role for cDC1s in converting poorly T cell-infiltrated tumors into heavily infiltrated TMEs, and identified a combinatorial immunotherapeutic regimen to engage them for robust CD4+ and CD8+ T cell-mediated tumor regression, resulting in the reversal of resistance to anti-PD-L1 therapy. Here, CD8A is linked to neoplasm.